Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8101)
All Articles published online
|
Publishing Process of This Article
|
Aug 10, 2014 (publication date) through Nov 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Mustonen MV, Pyrhönen S, Kellokumpu-Lehtinen PL. Toremifene in the treatment of breast cancer. World J Clin Oncol 2014; 5(3): 393-405 [PMID: 25114854 DOI: 10.5306/wjco.v5.i3.393] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v5/i3/393.htm |
| Number | Citing Articles |
| 1 |
Yinnan Chen, Yanmin Zhang. Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer. Advanced Science 2018; 5(6) doi: 10.1002/advs.201700964
|
| 2 |
Rola El Sayed, Lara El Jamal, Sarah El Iskandarani, Jeries Kort, Mahmoud Abdel Salam, Hazem Assi. Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00510
|
| 3 |
Yufei Ma, Weidong Li, Kai Ma, Tianyun Wang, Huigen Feng. Cell Surface Markers and their Targeted Drugs in Breast Cancer. Current Protein & Peptide Science 2022; 23(5): 335 doi: 10.2174/1389203723666220530102720
|
| 4 |
Sevann Helo, Blake Wynia, Andrew McCullough. “Cherchez La Femme”: Modulation of Estrogen Receptor Function With Selective Modulators: Clinical Implications in the Field of Urology. Sexual Medicine Reviews 2017; 5(3): 365 doi: 10.1016/j.sxmr.2017.03.003
|
| 5 |
Xin Li, Zehao Li, Lin Li, Tong Liu, Cheng Qian, Yanlv Ren, Zhigao Li, Kejin Chen, Dongchen Ji, Ming Zhang, Jinsong Wang. Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes. Cancer Research and Treatment 2024; 56(1): 134 doi: 10.4143/crt.2023.652
|
| 6 |
Kaat De Cremer, Nicolas Delattin, Katrijn De Brucker, Annelies Peeters, Soña Kucharíková, Evelien Gerits, Natalie Verstraeten, Jan Michiels, Patrick Van Dijck, Bruno P. A. Cammue, Karin Thevissen.
Oral Administration of the Broad-Spectrum Antibiofilm Compound Toremifene Inhibits Candida albicans and Staphylococcus aureus Biofilm Formation
In Vivo
. Antimicrobial Agents and Chemotherapy 2014; 58(12): 7606 doi: 10.1128/AAC.03869-14
|
| 7 |
Satyanarayana Murthy Malladi, Surya Prabha Sadhu, Devendra Kumar Pandey, Nagendra Sastry Yarla. Molecular Docking Studies and In-silico ADMET Profile Analysis of Triphala Plant constituents Morin and 9, 10-anthraquinone as Potential Inhibitors of human Estrogen Receptor Alpha. Research Journal of Pharmacy and Technology 2023; : 3759 doi: 10.52711/0974-360X.2023.00621
|
| 8 |
Wenxia Wang, Xiao’an Liu. Comparison of effects of tamoxifen and Toremifene on hepatic function and serum lipids in breast cancer patients during adjuvant endocrine therapy. Anti-Cancer Drugs 2024; 35(4): 371 doi: 10.1097/CAD.0000000000001572
|
| 9 |
Javier Rivero, Octavio P. Luzardo, Luis A. Henríquez-Hernández, Rubén P. Machín, José Pestano, Manuel Zumbado, Luis D. Boada, María Camacho, Pilar F. Valerón. In vitro evaluation of oestrogenic/androgenic activity of the serum organochlorine pesticide mixtures previously described in a breast cancer case–control study. Science of The Total Environment 2015; 537: 197 doi: 10.1016/j.scitotenv.2015.08.016
|
| 10 |
Dandan Song, Yingying Hu, Biyu Diao, Rongrong Miao, Baodan Zhang, Yangjun Cai, Hanqian Zeng, Yuru Zhang, Xiaoqu Hu. Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer. BMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-08538-5
|
| 11 |
Xiaoyou Wang, Xianhui Chen, Xiucong Yang, Wei Gao, Bing He, Wenbing Dai, Hua Zhang, Xueqing Wang, Jiancheng Wang, Xuan Zhang, Zhifei Dai, Qiang Zhang. A nanomedicine based combination therapy based on QLPVM peptide functionalized liposomal tamoxifen and doxorubicin against Luminal A breast cancer. Nanomedicine: Nanotechnology, Biology and Medicine 2016; 12(2): 387 doi: 10.1016/j.nano.2015.12.360
|
| 12 |
Jing Hu, Bi-Yue Zhu, Zhen-Xi Niu. Catalysts of Healing: A Symphony of Synthesis and Clinical Artistry in Small-Molecule Agents for Breast Cancer Alleviation. Molecules 2024; 29(5): 1166 doi: 10.3390/molecules29051166
|
| 13 |
Santiago Palacios. Postmenopausal Diseases and Disorders. 2019; : 349 doi: 10.1007/978-3-030-13936-0_23
|
| 14 |
Noura Al-Zeheimi, Sirin A. Adham. Latest Research on Breast Cancer [Working Title]. 2024; doi: 10.5772/intechopen.1007394
|
| 15 |
|
| 16 |
Pratap S. Dabhade, Manjushri P. Dabhade, Lala S. Rathod, Sachin A. Dhawale, Shweta A. More, Somdatta Y. Chaudhari, Santosh N. Mokale. Novel Pyrazole‐Chalcone Hybrids: Synthesis and Computational Insights Against Breast Cancer. Chemistry & Biodiversity 2024; 21(7) doi: 10.1002/cbdv.202400015
|
| 17 |
Yusuf Muhammed, Abduljalal Yusuf Nadabo, Mkpouto Pius, Bashiru Sani, Jafar Usman, Nasir Anka Garba, Jaafaru Mohammed Sani, Basit Opeyemi Olayanju, Sunday Zeal Bala, Musa Garba Abdullahi, Misbahu Sambo. SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development: A review. Biosafety and Health 2021; 3(5): 249 doi: 10.1016/j.bsheal.2021.07.003
|
| 18 |
William R. Martin, Feixiong Cheng. Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. Journal of Proteome Research 2020; 19(11): 4670 doi: 10.1021/acs.jproteome.0c00397
|
| 19 |
Mohini Chaurasia, Romi Singh, Srija Sur, S. J. S. Flora. A review of FDA approved drugs and their formulations for the treatment of breast cancer. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1184472
|
| 20 |
Veronica Preda, Ilampirai Rathinam , Louise Jin, Anna Nguyen , Juliana Chen. Systematic review of the risk of type 2 diabetes post therapy for early-stage breast cancer. Academia Oncology 2024; 1(1) doi: 10.20935/AcadOnco6242
|
| 21 |
Dandan Xia, Huiyu Wang, Runjie Wang, Chaoying Liu, Junying Xu. High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney. Medicine 2018; 97(24): e11115 doi: 10.1097/MD.0000000000011115
|
| 22 |
Olabayo H. Ajetunmobi, Gina Wall, Bruna Vidal Bonifacio, Lucero A. Martinez Delgado, Ashok K. Chaturvedi, Laura K. Najvar, Floyd L. Wormley, Hoja P. Patterson, Nathan P. Wiederhold, Thomas F. Patterson, Jose L. Lopez-Ribot. High-Throughput Screening of the Repurposing Hub Library to Identify Drugs with Novel Inhibitory Activity against Candida albicans and Candida auris Biofilms. Journal of Fungi 2023; 9(9): 879 doi: 10.3390/jof9090879
|
| 23 |
Franco Lumachi, Davide A Santeufemia, Stefano MM Basso. Current medical treatment of estrogen receptor-positive breast cancer. World Journal of Biological Chemistry 2015; 6(3): 231-239 doi: 10.4331/wjbc.v6.i3.231
|
| 24 |
Yeo-Jin Choi, Keunhyeong Bak, Yoon Yeo, Yongwon Choi, Sooyoung Shin. Incident Type 2 Diabetes Risk of Selective Estrogen Receptor Modulators in Female Patients with Breast Cancer. Pharmaceuticals 2021; 14(9): 925 doi: 10.3390/ph14090925
|
| 25 |
Xiaojing Yang, Yi Sun, Hongling Li, Yuhui Shao, Depeng Zhao, Weiwei Yu, Jie Fu. C-terminal binding protein-2 promotes cell proliferation and migration in breast cancer via suppression of p16INK4A. Oncotarget 2017; 8(16): 26154 doi: 10.18632/oncotarget.15402
|
| 26 |
|
| 27 |
Anushka Dashputra, Yashasvi Therkar, Atharva Balpande, Nikhil Khanwani, Aryan Wasewar, Ganesh C. Patil, Abhaykumar M. Kuthe, Satyendra Chandra Tripathi, Shilpa Deshpande, Surendar Kannaiyan, C. Ravikumar. Evaluation of tamoxifen analogues as potential estrogen receptor alpha inhibitors for breast cancer treatment: A computational approach. Journal of Molecular Liquids 2024; 414: 126209 doi: 10.1016/j.molliq.2024.126209
|
| 28 |
|
| 29 |
Neil J. McKenna. Research Resources for Nuclear Receptor Signaling Pathways. Molecular Pharmacology 2016; 90(2): 153 doi: 10.1124/mol.116.103713
|
| 30 |
|